Please login to the form below
Verzenios
This page shows the latest Verzenios news and features for those working in and with pharma, biotech and healthcare.
Eli Lilly’s Verzenios recommended by NICE as combination therapy for early-stage breast cancer
The trial results showed a drop of 32% in cancer recurrence when using Verzenios in combination with endocrine therapy. ... The trial showed that adjuvant treatment using Verzenios in combination with endocrine therapy decreased the risk of breast cancer
Latest news
-
NICE approval for Lilly's Verzenios is “fantastic news for thousands of women”
CDK4/6 inhibitors like Verzenios block proteins in cancer cells, stopping them from dividing and growing. ... However, Verzenios plus fulvestrant will now be available in England and Wales for the treatment of women with hormone receptor-positive,
-
NICE gives Lilly’s Verzenios chance to compete with rivals
Ibrance and Verzenios gained NICE approval in November 2017, which means Lilly has some catching up to do. ... Verzenios’ UK list price is the same as its rivals, £2, 950, but each has had to offer a confidential discount in order to gain NICE approval
-
Alnylam’s amyloidosis drug heads latest crop of CHMP approvals
CDK4/6 inhibitor Verzenios (abemaciclib) for hormone receptor-positive, HER2-negative breast cancer, already approved in the US (as Verzenio) and trying to chase down Pfizer’s category leader Ibrance (palbociclib).
More from news
Approximately 3 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- MHRA to introduce new UK clinical trials framework
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
- The Considered appoints Bam Zahraie as chief experience officer
PMHub
CHASE
We are a leading provider of outsourced commercial, medical and recruitment services to UK pharmaceutical, biotech and healthcare companies....
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
